North America Is Expected To Hold The Largest Share In The Global Adult Vaccines Market

 

Adult Vaccines Market

The growing prevalence and incidence of infectious diseases such as COVID-19 around the globe are positively shaping the growth of the adult vaccine market. According to the World Health Organization, globally, as of 6 April 2021, there have been 131,487,572 confirmed cases of COVID-19, including 2,857,702 deaths. Adult vaccines are used to prevent infections such as influenza, hepatitis, pneumococcal, tetanus, and pertussis. The government is taking initiatives to raise awareness regarding infectious diseases which has significantly elevated the demand for adult vaccines for the prevention of such diseases. Many companies are conducting clinical trials to develop a vaccine with high efficacy and improved safety. This is again fostering the growth of the adult vaccines market.

A vaccine is a biological preparation that offers strong individuals acquired protection against a specific disease. A typical vaccine generally contains an antigen that looks like a disease-causing virus and is frequently created from killed or weakened forms of this virus, its proteins, or some of its lipids. The amount of virus needed to produce sufficient quantities of vaccine usually requires a series of injections.  Some of the adult vaccines being used today are Gavi vaccine, Prevacid, Rubella vaccine, Mumps vaccine, and Trivium. These are all vaccines that have been given to millions of people and have shown effective results in preventing outbreaks of illness.

1.      In April 2020, GSK launched a national campaign to help increase low rates of vaccination among older adults. The campaign, Brought to You By Vaccines, will educate adults ages 50 and older about the value of vaccines and the urgent need to talk to their healthcare provider or pharmacist about the recommended vaccines they need or may have recently missed.

2.      In July 2019, The Indian Council of Medical Research (ICMR) has launched the third-phase trials for an anti-Tuberculosis vaccine that could be administered to anybody aged six years and above

3.      In December 2020, Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults

North America is expected to represent the largest market for adult vaccines. This is attributed to the presence of a well-established healthcare industry coupled with the growing number of clinical trials in the region. Moreover, the government in the region is initiatives so that everyone should receive vaccines in order to prevent the spread of COVID-19 infection. For instance, in the U.S., more Americans have received at least one dose than having tested positive for the virus since the pandemic began. So far, 169 million doses have been given. At in beginning of April 2021, an average of 3 million doses per day were administered.

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)